KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Jazz Pharmaceuticals (JAZZ) Short-term Investments (2016 - 2017)

Jazz Pharmaceuticals (JAZZ) has 4 years of Short-term Investments data on record, last reported at $200.0 million in Q3 2017.

For Q3 2017, Short-term Investments rose 236.6% year-over-year to $200.0 million; the TTM value through Sep 2017 reached $200.0 million, up 236.6%, while the annual FY2016 figure was $60.0 million, N/A changed from the prior year.
Short-term Investments reached $200.0 million in Q3 2017 per JAZZ's latest filing, up from $80.0 million in the prior quarter.
Across five years, Short-term Investments topped out at $200.0 million in Q3 2017 and bottomed at $764000.0 in Q1 2016.